Date published: 2026-7-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

HS3ST1 CRISPR/Cas9 KO Plasmid (h): sc-405358

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • HS3ST1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the HS3ST1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    HS3ST1 CRISPR/Cas9 KO Plasmid (h)

    sc-405358
    20 µg
    $397.00

    Overview

    HS3ST1 encodes heparan sulfate-glucosamine 3-O-sulfotransferase 1, a Golgi-localized enzyme that catalyzes 3-O-sulfation of heparan sulfate chains, generating rare motifs that modulate protein–glycosaminoglycan interactions. By shaping heparan sulfate fine structure, HS3ST1 influences extracellular matrix organization and cell-surface co-receptor functions that tune signaling pathways involving growth factors, chemokines, and morphogens. Altered heparan sulfate sulfation patterns are linked to changes in cell adhesion, migration, and inflammatory signaling, processes frequently implicated in tumor biology and neurodevelopmental phenotypes. As a determinant of heparan sulfate structure, HS3ST1 is studied for its role in regulating ligand binding and downstream signaling dynamics across diverse cellular contexts.

    HS3ST1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the HS3ST1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the HS3ST1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the HS3ST1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HS3ST1 protein expression.

    This CRISPR knockout system enables efficient generation of HS3ST1-deficient cell models for investigation of HS3ST1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting HS3ST1 exon(s) critical for HS3ST1 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple HS3ST1 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by HS3ST1 CRISPR/Cas9 KO Plasmid (h) and HS3ST1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the HS3ST1 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by HS3ST1 HDR Plasmid (h) and HS3ST1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by HS3ST1 homology arms to support homology-directed repair at defined HS3ST1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.